The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Review Article

Mood Stabilizers Are the First Line of Treatment for Bipolar Disorder

Authors: Shaishav Shah, MD, Kirolos Ibrahim, MD, Ahmed Sadah, MD, Rif S. El-Mallakh, MD

Abstract

Although lithium and other mood stabilizers remain the preferred agents for bipolar disorder, their clinical use has been declining steadily while antipsychotic and antidepressant use has been increasing. We performed an integrative review of efficacy, mechanisms of disease, and drug effects. The most reproduced biologic abnormality during the ill phases of bipolar disorder is elevated intracellular sodium. This has been proposed to directly lead to the symptoms of the disease. Lithium and mood stabilizers directly reduce or normalize intracellular sodium concentrations. Dopamine D2 receptor blockade by antipsychotic agents indirectly increases sodium pump activity, thereby also reducing intracellular sodium. Antidepressants increase intracellular sodium, which is believed to contribute to the destabilization of the illness. Lithium and mood-stabilizing anticonvulsant drugs inhibit sodium entry in an activity-dependent fashion that may directly normalize documented biologic abnormalities in manic or depressed bipolar patients. This action makes them the preferred first-line pharmacologic agents. Antipsychotic medication indirectly lower intracellular sodium and would be reasonable adjunctive or second-line agents. Serotoninergic antidepressants increase intracellular sodium, which may explain why they destabilize the illness and should be avoided or used as third-line agents.
Posted in: Psychiatry12 Mood Disorders1

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey initiative. Arch Gen Psychiatry 2011;68:241-251.
2. Rhee TG, Olfson M, Nierenberg AA, et al. 20-year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry 2020;177:706-715.
3. He H, Hu C, Ren Z, et al. Trends in the incidence and DALYs of bipolar disorder at global, regional, and national levels: results from the Global Burden of Disease Study 2017. J Psychiatr Res 2020;125:96-105.
4. McGuffin P, Rijsdijk F, Andrew M, et al. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003;60:497-502.
5. de Sousa RT, Zarate CA, Jr Zanetti MV, et al. Oxidative stress in early stage bipolar disorder and the association with response to lithium. J Psychiatr Res 2014;50:36-41.
6. Sochocka M, Diniz BS, Leszek J. Inflammatory response in the CNS: friend or foe? Mol Neurobiol 2017;54:8071-8089.
7. Freitas TP, Rezin GT, Fraga DB, et al. Mitochondrial respiratory chain activity in an animal model of mania induced by ouabain. Acta Neuropsychiatr 2011;23:106-111.
8. Mack AA, Gao Y, Ratajczak MZ, et al. Review of animal models of bipolar disorder that alter ion regulation. Neurosci Biobehav Rev 2019;107:208-214.
9. Hu M, Gao Y, El-Mallakh RS. Bipolar disorder-derived olfactory neuroepithelial progenitors more susceptible to glutamate induced apoptosis and lithium rescue than cells from non-bipolar subjects. J Affect Disord 2021;294:568-573.
10. Rybakowski J. Etiopathogenesis of bipolar affective disorder-the state of the art for 2021. Psychiatr Pol 2021;55:481-496.
11. Askland K. Toward a biaxial model of 𠇋” affective disorders: further exploration of genetic, molecular and cellular substrates. J Affect Disord 2006;94:35-66.
12. Askland K, Read C, Moore J. Pathways-based analyses of whole- genome association study data in bipolar disorder reveal genes mediating ion channel activity and synaptic neurotransmission. Hum Genet 2009;125:63-79.
13. El-Mallakh RS, Huff MO. Mood stabilizers and ion regulation. Harv Rev Psychiatry 2001;9:23-32.
14. Mü TW, Leber M, Schulze TG, et al. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun 2014;5:3339.
15. El-Mallakh RS, Wyatt RJ. The Na,K-ATPase hypothesis for bipolar illness. Biol Psychiatry 1995;37:235-244.
16. Dubovsky SL, Daurignac E, Leonard KE. Increased platelet intracellular calcium ion concentration is specific to bipolar disorder. J Affect Disord 2014;164:38-42.
17. El-Mallakh RS, Li R, Worth CA, et al. Leukocyte transmembrane potential in bipolar illness. J Affect Disord 1996;41:33-37.
18. Harrison PJ, Hall N, Mould A, et al. Cellular calcium in bipolar disorder: systematic review and meta-analysis. Mol Psychiatry 2021;26:4106-4116.
19. Roberts RJ, Repass R, El-Mallakh RS. Effect of dopamine on intracellular sodium: a common pathway for pharmacological mechanism of action in bipolar illness. World J Biol Psychiatry 2010;11( 2 Pt 2 ):181-187.
20. Aydin IH, El-Mallakh RS. Concept article: antidepressant-induced destabilization in bipolar illness mediated by serotonin 3 receptor (5HT3). Bipolar Disord 2024;26:772-778.
21. Sleem A, El-Mallakh RS. Advances in the psychopharmacotherapy of bipolar disorder type I. Expert Opin Pharmacother 2021;22:1267-1290.
22. Armek CJ, Ritchie JM. On the permeability of mammalian non- myelinated fibers to sodium and to lithium ions. J Physiol 1963;165:130-140.
23. Huang X, Lei Z, El-Mallakh RS. Lithium normalizes elevated intracellular sodium. Bipolar Disord 2007;9:298-300.
24. Lai HC, Jan LY. The distribution and targeting of neuronal voltage-gated ion channels. Nat Rev Neurosci 2006;7:548-562.
25. Costa B, Vale N. Understanding lamotrigine’ role in the CNS and possible future evolution. Int J Mol Sci 2023;24:6050.
26. Rybakowski JK. Application of antipsychotic drugs in mood disorders. Brain Sci 2023;13:414.
27. Agid O, Mamo D, Ginovart N, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response-a double-blind PET study in schizophrenia. Neuropsychopharmacology 2007;32:1209-1215.
28. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple- treatments meta-analysis. Lancet 2011;378:1306-1315.
29. Harrison-Read P. Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors-a new analysis of data from the archives and implications for improved antimanic treatments. J Psychopharmacol 2008;23:899-907.
30. Maletic V, Raison C. Integrated neurobiology of bipolar disorder. Front Psychiatry 2014;5:98.
31. Nemeroff CB. The state of our understanding AQ9 of the pathophysiology and optimal treatment of depression: glass half full or half empty. Am J Psychiatry 2020;177:671-685.
32. Tondo L, Vazquez GH, Baldessarini RJ. Depression and mania in bipolar disorder. Curr Neuropharmacol 2017;15:353-358.
33. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-1722.
34. Citrome L. Olanzapine-fluoxetine combination for the treatment of bipolar depression. Expert Opin Pharmacother 2011;12:2751-2758.
35. Pacchiaroki I, Bond DJ, Baldessarini RJ. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013;170:1249-1262.
36. Amsterdam JD, Brunswick DJ. Antidepressant monotherapy for bipolar type II major depression. Bipolar Disord 2003;5:388-395.
37. Amsterdam JD, Lorenzo-Luaces L, Soeller I, et al. Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study. J Affect Disord 2015;185:31-37.
38. Goklieb N, Young AH. Antidepressants and bipolar disorder: the plot thickens. Am J Psychiatry 2024;181:575-577.
39. El-Mallakh RS, Vö PA, Ostacher MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: a STEP-BD randomized clinical trial. J Affect Disord 2015;184:318-321.
40. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010;71:372-380.
41. El-Mallakh RS, Ghaemi SN, Sagduyu K, et al. Antidepressant- associated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord 2008;111:372-377.
42. Altshuler LL, Sugar CA, McElroy SL, et al. Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double-blind comparison. Am J Psychiatry 2017;174:266-276.
43. Altshuler L, Kiriakos L, Calcagno J, et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001;62:612-616.
44. Konsman IP. Expanding the notion of mechanism to further understanding of biopsychosocial disorders? Depression and medically-unexplained pain as cases in point. Stud Hist Philos Sci 2024;103:123-136.
45. Pangaro L. The role and value of the basic sciences in medical education: the perspective of clinical education-students’ progress from understanding to action. Med Sci Educ 2010;20:225-233.
46. Woodruff DB, El-Mallakh RS, Thiruvengadam AP. Validation of a diagnostic screening blood test for bipolar disorder. Ann Clin Psychiatry 2012;24:135-139.
47. Ramesh S, Arachchige ASPM. Depletion of dopamine in Parkinson’ disease and relevant therapeutic options: a review of the literature. AIMS Neurosci 2023;10:200-231.
48. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949;2:349-352.
49. Malhi GS, Bell E, Jadidi M, et al. Countering the declining use of lithium therapy: a call to arms. Int J Bipolar Disord 2023;11:30.
50. Pahwa M, Elsayed OH, El-Mallakh RS. The paradox of vanishing lithium. Bipolar Disord 2023;25:97-98.
51. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20:97-170.
52. King M, Essick C. The geography of antidepressant, antipsychotic, and stimulant utilization in the United States. Health Place 2013;20:32-38.
53. Barton BB, Segger F, Fischer K, et al. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf 2020;19:295-314.
54. Sleem A. El-Mallakh RS. Adaptive changes to antipsychotics: their consequences and how to avoid them. Curr Psychiatry 2022;21:46-50. 52.
55. Zhou XD, Chen QF, Yang W, et al. Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021. EClinicalMedicine 2024;76:102848.
56. Arslanian S, Bacha F, Grey M, et al. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. Diabetes Care 2018;41:2648-2668.